Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alba A Brandes

Showing results (61-70 of 178) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)Alba A Brandes, Alicia Tosoni, Umberto Basso, et al.
Oncotarget|July 14, 2016
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastomaSalveena Schiffgens, Ludwig Wilkens, Alba A Brandes, et al.
Future Oncology (London, England)|June 21, 2014
Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?Alba A Brandes, Warren Mason, Josef Pichler, et al.
Cancer|June 11, 2009
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation statusAlba A Brandes, Enrico Franceschi, Alicia Tosoni, et al.
Cancer|January 28, 2003
A prospective study on glioblastoma in the elderlyAlba A Brandes, Francesca Vastola, Umberto Basso, et al.
Neuro-Oncology|May 26, 2006
Survival following adjuvant PCV or temozolomide for anaplastic astrocytomaAlba A Brandes, Linda Nicolardi, Alicia Tosoni, et al.
Journal of Neuro-Oncology|April 20, 2018
Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?Enrico Franceschi, Giuseppe Lamberti, Alexandro Paccapelo, et al.
Cancer|May 25, 2005
A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-OncologiaAlba A Brandes, Giovanna Cavallo, Michele Reni, et al.
Scientific Reports|March 15, 2018
Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1<sup>105GGT</sup>) in brain tumors of a cohort of Italian patientsGiorgia Acquaviva, Michela Visani, Dario de Biase, et al.
Future Oncology (London, England)|November 15, 2014
Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overviewGiovenzio Genestreti, Francesco Grossi, Carlo Genova, et al.
Pageof 18

Showing results (61-70 of 178) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)Alba A Brandes, Alicia Tosoni, Umberto Basso, et al.
Oncotarget|July 14, 2016
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastomaSalveena Schiffgens, Ludwig Wilkens, Alba A Brandes, et al.
Future Oncology (London, England)|June 21, 2014
Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?Alba A Brandes, Warren Mason, Josef Pichler, et al.
Cancer|June 11, 2009
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation statusAlba A Brandes, Enrico Franceschi, Alicia Tosoni, et al.
Cancer|January 28, 2003
A prospective study on glioblastoma in the elderlyAlba A Brandes, Francesca Vastola, Umberto Basso, et al.
Neuro-Oncology|May 26, 2006
Survival following adjuvant PCV or temozolomide for anaplastic astrocytomaAlba A Brandes, Linda Nicolardi, Alicia Tosoni, et al.
Journal of Neuro-Oncology|April 20, 2018
Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?Enrico Franceschi, Giuseppe Lamberti, Alexandro Paccapelo, et al.
Cancer|May 25, 2005
A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-OncologiaAlba A Brandes, Giovanna Cavallo, Michele Reni, et al.
Scientific Reports|March 15, 2018
Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1<sup>105GGT</sup>) in brain tumors of a cohort of Italian patientsGiorgia Acquaviva, Michela Visani, Dario de Biase, et al.
Future Oncology (London, England)|November 15, 2014
Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overviewGiovenzio Genestreti, Francesco Grossi, Carlo Genova, et al.
Pageof 18